Literature DB >> 2644154

A new measure of health status for clinical trials in inflammatory bowel disease.

G Guyatt1, A Mitchell, E J Irvine, J Singer, N Williams, R Goodacre, C Tompkins.   

Abstract

We have developed a measure of subjective health status (quality of life) for patients with inflammatory bowel disease (IBD). Ninety-seven patients with IBD described problems they had experienced as a result of the disease; the 32 most frequent and important items were included in the Inflammatory Bowel Disease Questionnaire (IBDQ). Sixty-one IBD patients were evaluated twice. One month separated the evaluations, at which disease activity indices, the IBDQ, and a number of other questionnaires were administered. Reproducibility studies in 19 stable patients showed improvement in scores, but also a small within-person standard deviation. Responsiveness studies revealed large changes in scores in patients who had improved or deteriorated and suggested that the IBDQ was more responsive than a general health status measure. Responsiveness appeared greater in patients with ulcerative colitis than in those with Crohn's disease. Predicted and observed correlations between changes in IBDQ score and changes in other measures were similar. We conclude that although further testing is required, particularly in examining the relation between changes in the IBDQ and changes in the activity of Crohn's disease, the IBDQ shows promise as a measure of health status for clinical trials in IBD.

Entities:  

Mesh:

Year:  1989        PMID: 2644154

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  260 in total

1.  Factors affecting health related quality of life of patients with inflammatory bowel disease.

Authors:  Francesc Casellas; Josefa López-Vivancos; Alfonso Casado; Juan-Ramon Malagelada
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 4.147

2.  Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS).

Authors:  Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Bjørn Moum
Journal:  Qual Life Res       Date:  2011-12-07       Impact factor: 4.147

Review 3.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 4.  Assessing disease activity and disease activity indices for inflammatory bowel disease.

Authors:  Feng Xiao Li; Lloyd R Sutherland
Journal:  Curr Gastroenterol Rep       Date:  2002-12

5.  Surgery for ulcerative colitis in children.

Authors:  Arnold G Coran; Massimo Rivosecchi
Journal:  Pediatr Surg Int       Date:  2004-08-06       Impact factor: 1.827

6.  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.

Authors:  E F Juniper; G H Guyatt; R S Epstein; P J Ferrie; R Jaeschke; T K Hiller
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

7.  Progress in the diagnosis and treatment of inflammatory bowel disease.

Authors:  Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

8.  Validation of the treatment satisfaction questionnaire for Crohn's disease (TSQ-C).

Authors:  Karin Coyne; Sandra Joshua-Gotlib; Miriam Kimel; Christine Thompson; Amy Lewis; Mervyn Danilewitz
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  Ileal pouch-anal anastomosis in ulcerative colitis: outcomes, functional results, and quality of life in patients with more than 10-year follow-up.

Authors:  L Carcamo; P Miranda; A Zúñiga; E Alexander; M E Molina; G Urrejola; T Larach; R Miguieles; Felipe Bellolio
Journal:  Int J Colorectal Dis       Date:  2020-02-18       Impact factor: 2.571

10.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors:  T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.